Our products
  • Lyfevalue

    Platform for value & data-driven agreements for manufacturers, healthcare payers and care providers.

  • Lyfeapp

    Next-generation patient management system created for healthcare professionals, nurses and care teams

Trump’s four executive orders to lower drug prices: what does this mean for value-based contracting & innovative drugs?

  • Author – Nico Mros
  • 3min read

On Friday, President Donald Trump signed four executive orders aimed at lowering the high cost of prescription drugs in the United States. Our COO, Nico Mros, dives into the four executive orders. 



“The four orders I’m signing today will completely restructure the prescription drug market in terms of pricing and everything else to make these medications affordable and accessible for all Americans,” Trump said at the White House last Friday.

Trump goes on to state that Americans often pay up to 80% higher prices for prescription drugs than countries like Germany and Canada.

And while the timing seems anything but coincidental, Lyfegen does not intend to discuss political views but rather understand what this could mean specifically for healthcare innovation, value-based contracting and the patients whose life depend on access to innovative therapies.

Let us briefly and in simple terms dissect the four executive orders, which are subject to the regulatory review process post Friday’s signature:

The first order targets high insulin prices and EpiPens, requiring federal community health centers to pass discounts they receive directly to patients.

The second order would allow states, pharmacies and wholesalers to import drugs from Canada, where prices are drastically lower. Importing drugs would increase competition and cause drug prices in the United States to decrease. Up until now, prices were maintained high because importing medications from other countries for personal use was illegal according to the Food and Drug Administration.

The third order is aimed at preventing “middlemen,” more commonly known in healthcare as health plan sponsors and pharmacy benefit managers (PBMs), to pocket “significant discounts” negotiated — these being “up to 50 percent of the cost of the drug” while retailing them without a discount.

The fourth order, which has been signed but is being held back until Aug. 24 to give the healthcare industry time to “come up with something” to reduce drug prices, would allow Medicare to purchase drugs at the same price as other countries by implementing a “international pricing index”.

The international pricing index would align U.S. prices to those of other countries, such as Britain, France and Canada – countries where the cost of the same drugs are substantially lower because Governments cap drug prices.

So what does this mean for pharmaceutical innovation?

Simply aligning prices to countries where governments cap drug prices (in the case of the fourth executive order) or opening the import of prescription drugs from neighboring countries (in the case of the second executive order) will result in billion dollar losses for pharmaceutical companies within the next decade, increasing the risk of losing the funds necessary to drive innovation substantially (specifically the Research & Development of cutting edge innovative therapies).

“We pay for all of the resources and all of the development and foreign countries pay absolutely nothing,” Trump said. “Americans are funding the enormous cost of drug resource for the entire planet.”

But could this mean that pharmaceutical companies, trying to compensate their losses, would (or better said, should) be forced to focus on the root problems of healthcare pricing and come up with more wide-spread innovative pricing models for a more sustainable future.

Value-based contracting and technological solutions, such as those of Lyfegen, could support such a future.

In a world where value-based pricing is the norm, world leaders would not only look over to neighboring countries for pricing levels but rather would have to focus on the value of drugs and how they improve patient health outcomes.

Pharmaceutical company executives were scheduled to meet at the White House today to discuss the executive orders but the meeting was cancelled. Moving forward, one can only hope that healthcare innovation can start coexisting with sustainable expenditure and patient access.

Close

BOOK A DEMO  1 / 2

Nice to see you!

Please fill out the form with
your personal details

Close

BOOK A DEMO  2 / 2

Select the solutions you are
interested in

Selected Solutions:

LyfevalueLyfeapp

BOOK A DEMO

Request sent!

We will be in touch with you as
soon as possible.

Close

Real life case study  1 / 1

Thanks for your interest in
our case study!

Please fill out the form with your personal
details to receive the case study via email

Download

Real life case study

The case study is on its way!

Please check your email inbox.

Close

Contact Us  1 / 1

Looking forward
to your message!

Contact us

Message Sent!

We will be in touch with you
as soon as possible.

Close

LOG IN  1 / 2

Selct product you
want log in to

Log in to:

Close

Apply for job  1 / 1

Ready to join the team?

We look forward to receiving your application!
Please fill out your info & we will be in touch.

Selected jobs:

Lead Full-Stack DeveloperProduct-owner/-leader

No file chosen, yet.
No file chosen, yet.

Apply for job

We will be in touch with you
as soon as possible.

Please check your email inbox.